XTLB XTL BIOPHARMACEUTICALS LTD IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1023549
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY42.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin0.7%
Operating margin-481.6%
Net margin-227.7%
FCF margin-370.7%
EBITDA margin—
Returns
ROE-26.8%
ROA-18.7%
ROIC (approx.)-58.3%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets36.4%
Debt / equity0.00x
Current ratio0.61x
Interest coverage-77.57x
Cash quality & payout
Operating cash flow / net income1.58x
Accruals ratio10.8%
Payout ratio—
Capex / revenue12.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $451,000 | — |
| Cost of revenue | $448,000 | — |
| Gross profit | $3,000 | — |
| R&D expense | $98,000 | $31,000 |
| SG&A expense | $1.59M | $734,000 |
| Operating income | -$2.17M | -$765,000 |
| Interest expense | $28,000 | — |
| Pretax income | -$1.16M | -$1.78M |
| Income tax | -$130,000 | — |
| Net income | -$1.03M | -$1.78M |
| EPS (basic) | -0.00 | -0.00 |
| EPS (diluted) | -0.00 | -0.00 |
| Weighted avg. shares (diluted) | 704.16M | 544.91M |
| Balance sheet | ||
| Cash & equivalents | $371,000 | $1.40M |
| Receivables | $99,000 | — |
| Current assets | $1.34M | $2.05M |
| PP&E, netmay include right-of-use assets (IFRS) | $187,000 | — |
| Goodwill | $3.19M | — |
| Intangibles | $3.82M | $380,000 |
| Total assets | $8.55M | $2.43M |
| Current liabilities | $2.21M | $206,000 |
| Short-term debt | $138,000 | — |
| Total liabilities | $3.12M | $206,000 |
| Shareholders' equity | $5.43M | $2.22M |
| Shares outstanding | 881.39M | 544.91M |
| Cash flow statement | ||
| Operating cash flow | -$1.62M | -$707,000 |
| Capital expenditure | $54,000 | — |
| Free cash flow | -$1.67M | — |
| Investing cash flow | -$844,000 | $41,000 |
| Financing cash flow | $1.45M | — |
| Stock-based compensation | $264,000 | $3,000 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.